Samumed Granted Orphan Drug Designation for SM08502 for the Treatment of Pancreatic Cancer
January 03, 2019 08:00 ET
|
Samumed
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that the U.S. Food and Drug Administration (FDA) granted orphan drug designation (ODD) for SM08502 for the treatment of...
Samumed Doses First Subject in Phase 2/3 Trial of SM04554 for the Treatment of Androgenetic Alopecia
November 19, 2018 08:00 ET
|
Samumed
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has dosed the first subject in its phase 2/3 trial of SM04554, a topical small molecule Wnt pathway activator, for...
Samumed Announces Multiple Presentations at 6th World Congress on Controversies, Debates & Consensus in Bone, Muscle & Joint Diseases (BMJD)
November 05, 2018 08:00 ET
|
Samumed
SAN DIEGO, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it will present clinical and preclinical data on the company’s small molecule Wnt pathway inhibitor, SM04690, in four...
Samumed Phase 2b Trial in Knee Osteoarthritis Meets Primary Endpoints
October 24, 2018 08:00 ET
|
Samumed
Pivotal phase 3 trials of SM04690 in knee osteoarthritis anticipated to begin early 2019 SAN DIEGO, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Samumed announced today top-line data from its phase 2b trial...
Samumed to Present Preclinical Data on SM07883 at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Congress
October 18, 2018 08:00 ET
|
Samumed
SAN DIEGO, Oct. 18, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it will present preclinical data on the company’s novel DYRK1A inhibitor, SM07883, a potential first-in-class drug for...
Samumed to Present Data from Phase 2b Trial of SM04690 for Treatment of Knee Osteoarthritis at 2018 American College of Rheumatology (ACR) Annual Meeting
October 16, 2018 08:00 ET
|
Samumed
Top-line Results to be Released as a Late-Breaking Presentation SAN DIEGO, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that data will be presented from a phase 2b trial of its...
Samumed Announces Sponsorship of Knee Osteoarthritis Registry Study
October 15, 2018 08:00 ET
|
Samumed
Collaboration will prospectively evaluate the natural history of knee osteoarthritis progression SAN DIEGO, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today its sponsorship of a...
Samumed Closes on $438 Million in Equity Financing
August 06, 2018 08:00 ET
|
Samumed
SAN DIEGO, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has closed its A-6 Round of equity issuance with $438 million, bringing its total equity raised to date to more...
Samumed Presents Positive Preclinical Data on SM07883 at 2018 Alzheimer’s Association International Conference® (AAIC®)
July 27, 2018 08:00 ET
|
SAMUMED
Data supports SM07883 as a potential treatment for chronic tauopathies such as Alzheimer’s disease Company expects SM07883 to enter first-in-man studies in fall 2018 SAN DIEGO, July 27, 2018 ...
Samumed to Present Preclinical Data on SM07883, a Potential First-in-Class Alzheimer’s Disease Candidate, at the Alzheimer’s Association International Conference® (AAIC®) 2018
July 17, 2018 08:00 ET
|
SAMUMED
SAN DIEGO, July 17, 2018 (GLOBE NEWSWIRE) -- Samumed, LLC, announced today that it has been selected to present preclinical data on the company’s novel DYRK1a inhibitor, SM07883, a potential...